Literature DB >> 22404727

Reversal of nonstructural protein 3-specific CD4(+) T cell dysfunction in patients with persistent hepatitis C virus infection.

M Bes1, S Sauleda, N Casamitjana, M Piron, I Campos-Varela, J Quer, M Cubero, L Puig, J Guardia, J I Esteban.   

Abstract

Hepatitis C virus (HCV)-specific T cell responses are essential for HCV control, and chronic infection is characterized by functionally altered antigen-specific T cells. It has been proposed that the early inactivation of specific CD4(+) T cell responses may be involved in establishment of HCV persistence. We have investigated whether HCV-specific CD4(+) T cells dysfunction can be reversed in vitro. Nonstructural protein 3 (NS3) and core-specific CD4(+) T cells from eight chronically infected and eight spontaneously resolved HCV individuals were selected through transient CD154 (CD40 ligand) expression, and their functional profile (IFN-γ, IL-2, TNF-α, IL-10 and IL-4 production by enzyme-linked immunospot assay, cytometric bead array and intracellular cytokine staining, and proliferation by carboxy-fluorescein diacetate succinimidyl ester dilution assay) was determined both ex vivo and after in vitro expansion of sorted CD154-expressing cells in the absence of specific antigen in IL-7/IL-15-supplemented medium. Ex vivo bulk CD4(+) T cells from chronic patients expressed CD154 in most cases, albeit at lower frequencies than those of resolved patients (0.11%vs 0.41%; P = 0.01), when stimulated with NS3, but not core, although they had a markedly impaired capacity to produce IL-2 and IFN-γ. Antigen-free in vitro expansion of NS3-specific CD154(+) cells from chronic patients restored IFN-γ and IL-2 production and proliferation to levels similar to those of patients with spontaneously resolved infection. Hence, NS3-specific CD4(+) T cell response can be rescued in most chronic HCV patients by in vitro expansion in the absence of HCV-specific antigen. These results might provide a rationale for adoptive immunotherapy.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22404727     DOI: 10.1111/j.1365-2893.2011.01549.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

Review 1.  Autologous regulatory T cells for the treatment of type 1 diabetes.

Authors:  James A Thompson; Daniel Perry; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

2.  Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunity.

Authors:  Tom Pembroke; Ian Rees; Kathleen Gallagher; Emma Jones; Paul Mizen; Timur Navruzov; Andrew Freedman; Ceri Fielding; Ian R Humphreys; Eddie C Y Wang; Awen M Gallimore; Andrew Godkin
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

Review 3.  Advanced molecular surveillance of hepatitis C virus.

Authors:  Livia Maria Gonçalves Rossi; Alejandro Escobar-Gutierrez; Paula Rahal
Journal:  Viruses       Date:  2015-03-13       Impact factor: 5.048

4.  The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response.

Authors:  P Muñoz de Rueda; S M Jiménez-Ruiz; R Quiles; E J Pavón-Castillero; J A Muñoz-Gámez; J Casado; A Gila; A Ruiz-Extremera; J Salmerón
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

Review 5.  Methodologies for the Analysis of HCV-Specific CD4(+) T Cells.

Authors:  Megha U Lokhande; Robert Thimme; Paul Klenerman; Nasser Semmo
Journal:  Front Immunol       Date:  2015-02-25       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.